Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.

Thrombosis and haemostasis - 1 Aug 2012

Jilma-Stohlawetz Petra, Knöbl Paul, Gilbert James C, Jilma Bernd

Abstract excerpt

Blockade of hyperactive von Willebrand factor (VWF) by ARC1779 blunted the platelet drop induced by desmopressin in patients with type 2B von Willebrand disease (VWD). Thus, we hypothesised that ARC1779 may increase VWF levels and correct thrombocytopenia. Three thrombocytopenic patients sufferin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aptamers, Nucleotide
Share to Blood Platelets
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Count

Share to Thrombocytopenia

Share to Time Factors

Share to von Willebrand Disease, Type 2

Share to von Willebrand Factor

Source

Identifiers

PMID: 22740102
DOI: 10.1160/TH11-12-0889

Genes

VWF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22740102-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.PMID 22740102Read ↗

First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy VolunteersSemantic proximity Read ↗

Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand diseaseSemantic proximity Read ↗

Treatment of von Willebrand DiseaseSemantic proximity Read ↗

Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.Semantic proximity Read ↗

von Willebrand disease: what does the future hold?Semantic proximity Read ↗

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read ↗

Advances in the genetics and treatment of von Willebrand disease.Semantic proximity Read ↗

Thrombocytapheresis as a Bridge Intervention in JAK2-Mutant Myeloproliferative Neoplasm Complicated by Acquired von Willebrand Disease: A Case Report.Semantic proximity Read ↗

Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group.Semantic proximity Read ↗

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1Semantic proximity Read ↗

The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.Semantic proximity Read ↗

von Willebrand factor to the rescueSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.